Advanced Proteome Therapeutics Corporation Attending JP Morgan Healthcare Conference Week January 10-14th, 2016

VANCOUVER, BC--(Marketwired - January 04, 2016) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) will be attending the Biotech Showcase Conference, held in San Francisco during the 34^th Annual JP Morgan Healthcare Conference week, January 10^th - 14^th, 2016.

The Company is actively looking to partner its extensive IP portfolio, know-how and technologies for the development of superior protein therapeutics for cancer and other novel applications. APC's attendance at the Conference will focus on exploring partnership opportunities.

"We have built an innovative portfolio of protein modification technologies and early stage targeted immunotherapeutic product candidates. Through our partnering activities, we will look for opportunities to create value for both APC and our partner companies," said Allen Krantz, President and CEO of APC.

APC has engaged Ella Korets-Smith, Principal at EKS Business Development, to lead the Company's business development effort. Ms. Korets-Smith has established a track record of closing deals and leading successful marketing and business development programs. Previous to APC, Ms. Korets-Smith held senior business development and marketing positions at Immunovaccine Inc., Nordion Inc. and Synergy Health plc. Ms. Korets-Smith has an MSc in Medical Genetics from the University of Toronto and an MBA from Dalhousie University.

To book a meeting with APC during the JP Morgan Healthcare Conference week or to learn more about the opportunity, please contact Ella Korets-Smith at ella@advancedproteome.com. 

About APC

Advanced Proteome Therapeutics Corporation (APC) is advancing a Site-Specific Protein Modification technology platform to enable the development of superior protein therapeutics. Using this technology, the company has generated numerous and diverse modifications of Annexin V with superior binding and stability properties and are amenable to further labeling and conjugation for use in therapeutic applications. APC has preliminary data in pre-clinical animal models which show the potential of a number such entities, including APC 101, to act as an immunotherapeutic agent for cancer therapy. The company is also engaged in creating annexin-drug conjugates to rival antibody-drug conjugates and has prepared examples of such novel species.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.